Novartis Confident About Transforming CSU Landscape
And Has High Hopes For CAR-T In Immunology
With its BTK inhibitor remibrutinib advancing through Phase III trials and work getting started on a CAR-T therapy for lupus, Novartis’s Marie-France Tschudin tells Scrip that the Swiss major’s immunology pipeline is in a healthy state.
You may also be interested in...
Adding to a growing pattern within the BTK inhibitor pipeline for multiple sclerosis, the US FDA has placed Merck’s evobrutinib on a partial clinical hold following two liver injury incidents, prompting questions over its ultimate approvability.
The firm’s BTK inhibitor tolebrutinib has been put on clinical hold by the US FDA following liver injuries, but advanced trials should continue as normal since most patients have passed the 60-day mark.
Novartis’s ligelizumab failed to show superiority over standard of care Xolair, subverting hopeful analyst expectations and changing the firm’s focus in chronic spontaneous urticaria to a BTK inhibitor asset.